Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 203

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer

Open access
de Bruin, Elza C., Cowell, Catherine, Warne, Patricia H., Jiang, Ming, Saunders, Rebecca E., Melnick, Mary Ann, Gettinger, Scott, Walther, Zenta, Wurtz, Anna, Heynen, Guus J., Heideman, Daniëlle A.M., Gómez-Román, Javier, García-Castaño, Almudena, Gong, Yixuan, Ladanyi, Marc, Varmus, Harold, Bernards, René, Smit, Egbert F., Politi, Katerina, Downward, Julian·2014·Cancer Discovery

Abstract

Activating mutations in the EGF receptor (EGFR) are associated with clinical responsiveness to EGFR tyrosine kinase inhibitors (TKI), such as erlotinib and gefitinib. However, resistance eventually arises, often due to a second EGFR mutation, most commonly T790M. Through a genome-wide siRNA screen in a human lung cancer cell line and analyses of murine mutant EGFR-driven lung adenocarcinomas, we found that erlotinib resistance was associated with reduced expression of neurofibromin, the RAS GTPase-activating protein encoded by the NF1 gene. Erlotinib failed to fully inhibit RAS–ERK signaling when neurofibromin levels were reduced. Treatment of neurofibromin-deficient lung cancers with a MAP–ERK kinase (MEK) inhibitor restored sensitivity to erlotinib. Low levels of NF1 expression were associated with primary and acquired resistance of lung adenocarcinomas to EGFR TKIs in patients. These findings identify a subgroup of patients with EGFR-mutant lung adenocarcinoma who might benefit from combination therapy with EGFR and MEK inhibitors. Significance: The emergence of resistance to EGFR TKIs is a major clinical challenge in the treatment of lung adenocarcinomas driven by mutations in EGFR. This study suggests that, in a subset of patients, resistance is caused by reduced neurofibromin expression, and that in these cases there may be clinical benefit to combining EGFR TKIs with MEK inhibitors. Cancer Discov; 4(5); 606–19. ©2014 AACR. See related commentary by Maertens and Cichowski, p. 519 This article is highlighted in the In This Issue feature, p. 495

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0741

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 203

Metadata

Authors
de Bruin, E. C., Cowell, C., Warne, P. H., Jiang, M., Saunders, R. E., Melnick, M. A., Gettinger, S., Walther, Z., Wurtz, A., Heynen, G. J., Heideman, D. A. M., Gómez-Román, J., García-Castaño, A., Gong, Y., Ladanyi, M., Varmus, H., Bernards, R., Smit, E. F., Politi, K., & Downward, J.
Venue
Cancer Discovery
Published
2014-05-01
Volume
4
Issue
5
Pages
606-619
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2117784514
Cited by
203
References
18
FWCI
15.27
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-13-0741
The paper
de Bruin, E. C., Cowell, C., Warne, P. H., Jiang, M., Saunders, R. E., Melnick, M. A., Gettinger, S., Walther, Z., Wurtz, A., Heynen, G. J., Heideman, D. A. M., Gómez-Román, J., García-Castaño, A., Gong, Y., Ladanyi, M., Varmus, H., Bernards, R., Smit, E. F., Politi, K., & Downward, J. (2014). Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-13-0741

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.